Report cover image

Oncology Precision Medicine Market

Publisher Global Market Insights
Published Nov 05, 2024
Length 111 Pages
SKU # GMI19407281

Description

Oncology Precision Medicine Market


The Global oncology precision medicine market reached USD 53.2 billion in 2023 and is projected to expand at a CAGR of 10.4% from 2024 to 2032. A key factor driving the growth of this market is the rising incidence of cancer. With an increasing number of cancer diagnoses, there is a heightened demand for personalized treatment options that target specific genetic mutations, ultimately enhancing treatment outcomes. This trend highlights the necessity for precision oncology therapies that provide targeted, effective treatments with minimal side effects, thus improving patients' quality of life.Moreover, the market is rapidly advancing due to a greater understanding of cancer genomics and the introduction of cutting-edge technologies like next-generation sequencing (NGS) and liquid biopsy. These innovations facilitate the identification of specific genetic mutations and biomarkers, helping oncologists select the most suitable targeted therapies or immunotherapies for individual patients.In terms of cancer types, the market encompasses various categories, including breast cancer, lung cancer, hematologic cancers, gastrointestinal cancers, skin cancer, and several others. The breast cancer segment led the market with a 22.3% share in 2023, as precision medicine focuses on targeted therapies addressing specific genetic mutations associated with this type of cancer. By emphasizing molecular profiling and customized treatment plans, this segment has gained significant traction in the market.When considering routes of administration, the oncology precision medicine market is divided into oral, intravenous, and other delivery methods. The oral segment alone was valued at USD 26.8 billion in 2023 and is expected to grow at a CAGR of 10.2% during the forecast period. This growth can be attributed to the growing inclination for oral medicines, which offer greater convenience compared to intravenous options. The rise of targeted therapies in precision medicine has also bolstered the oral segment, as many oncology drugs, including kinase inhibitors, are formulated as oral medications. This allows for more precise targeting of cancer cells based on the unique genetic makeup of individual tumors.North America oncology precision medicine market reached USD 21.3 billion in 2023 and is forecasted to grow at a CAGR of 10.2% from 2024 to 2032. The growth in this region is primarily fueled by a high prevalence of cancer and a robust healthcare infrastructure that supports innovative research and development. Investments from both the public and private sectors in cancer research stimulate innovation, while regulatory bodies expedite the approval process for precision therapies. Increased awareness of personalized medicine among healthcare providers and patients further enhances adoption rates, driving market expansion.

Table of Contents

111 Pages
Chapter 1 Methodology
1.1 Market segmentation
1.2 Market definitions
1.3 Research design
1.4 Market size estimates and calculations
1.4.1 Approach 1: Revenue share analysis
1.4.2 Approach 2: Parent market analysis
1.4.3 Approach 2: Bottom-up approach
1.4.4 Key trends for market estimates
1.5 Forecast model
1.6 Primary research & validation
1.6.1 Primary sources
1.6.2 Data mining sources
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Global market 360° synopsis, 2021- 2032 (USD Billion)
2.1.1 Business trends
2.1.2 Cancer type trends
2.1.3 Route of administration trends
2.1.4 Molecule type trends
2.1.5 Drug class trends
2.1.6 Regional trends
Chapter 3 Oncology Precision Medicine Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cancer
3.2.1.2 Increasing awareness and shift towards personalized therapies
3.2.1.3 Technological advancements
3.2.2.1 High cost of precision medicine
3.2.2.2 Complex regulatory approval process
3.3 Growth potential analysis
3.3.1 By cancer type
3.3.2 By route of administration
3.3.3 By molecule type
3.3.4 By drug class
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Company market share analysis
4.5 Strategy dashboard
Chapter 5 Oncology Precision Medicine Market, By Cancer Type
5.1 Breast cancer
5.2 Lung cancer
5.3 Blood/hematologic cancer
5.4 Gastrointestinal cancer
5.5 Skin cancer
5.6 Bladder cancer
5.7 Cervical cancer
5.8 Head & neck squamous cell cancer
5.9 Other cancer types
Chapter 6 Oncology Precision Medicine Market, By Route of Administration
6.1 Oral 58
6.2 Intravenous
6.3 Other routes of administration
Chapter 7 Oncology Precision Medicine Market, By Molecule Type
7.1 Small molecules
7.2 Biologics
Chapter 8 Oncology Precision Medicine Market, By Drug Class
8.1 Kinase inhibitors
8.2 Immune checkpoint inhibitors
8.3 Enzyme inhibitors
8.4 Other drug classes
Chapter 9 Oncology Precision Medicine Market, By Region
9.1 North America
9.2 Europe
9.3 Asia Pacific
9.4 Latin America
9.5 MEA 67
Chapter 10 Company Profile
10.1 AbbVie Inc.
10.1.1 Global overview
10.1.2 Business overview
10.1.3 Financial data
10.1.3.1 Annual sales revenue, 2020-2023 (USD Million)
10.1.4 Product landscape
10.1.5 Strategic outlook
10.1.6 SWOT analysis
10.2 AstraZeneca
10.2.1 Global overview
10.2.2 Business overview
10.2.3 Financial data
10.2.3.1 Annual sales revenue, 2020-2023 (USD Million)
10.2.4 Product landscape
10.2.5 SWOT analysis
10.3 Bayer AG
10.3.1 Global overview
10.3.2 Business overview
10.3.3 Financial data
10.3.3.1 Annual sales revenue, 2020-2023 (USD Million)
10.3.4 Product landscape
10.3.5 Strategic outlook
10.3.6 SWOT analysis
10.4 Blueprint Medicines Corporation
10.4.1 Global overview
10.4.2 Business overview
10.4.3 Financial data
10.4.3.1 Annual sales revenue, 2020-2023 (USD Million)
10.4.4 Product landscape
10.4.5 Strategic outlook
10.4.6 SWOT analysis
10.5 Bristol-Myers Squibb Company
10.5.1 Global overview
10.5.2 Business Overview
10.5.3 Financial data
10.5.3.1 Annual sales revenue, 2020-2023 (USD Million)
10.5.4 Product Landscape
10.5.5 Strategic outlook
10.5.6 SWOT analysis
10.6 Eli Lilly and Company
10.6.1 Global overview
10.6.2 Business overview
10.6.3 Financial data
10.6.3.1 Annual sales revenue, 2020 - 2023 (USD Million)
10.6.4 Product landscape
10.6.5 Strategic outlook
10.6.6 SWOT analysis
10.7 F. Hoffmann-La Roche Ltd.
10.7.1 Global overview
10.7.2 Business overview
10.7.3 Financial data
10.7.3.1 Annual sales revenue, 2020-2023 (USD Million)
10.7.4 Product landscape
10.7.5 Strategic outlook
10.7.6 SWOT analysis
10.8 GlaxoSmithKline plc
10.8.1 Global overview
10.8.2 Business overview
10.8.3 Financial data
10.8.3.1 Annual sales revenue, 2020-2023 (USD Million)
10.8.4 Product landscape
10.8.5 Strategic outlook
10.8.6 SWOT analysis
10.9 Merck KGaA
10.9.1 Global overview
10.9.2 Business overview
10.9.3 Financial data
10.9.3.1 Annual sales revenue, 2023-2020 (USD Million)
10.9.4 Product landscape
10.9.5 SWOT analysis
10.10 Novartis AG
10.10.1 Global overview
10.10.2 Business overview
10.10.3 Financial data
10.10.3.1 Annual sales revenue, 2020-2023 (Euro Million)
10.10.4 Product landscape
10.10.5 Strategic outlook
10.10.6 SWOT analysis
10.11 Organon & Co.
10.11.1 Global overview
10.11.2 Business overview
10.11.3 Financial data
10.11.3.1 Annual sales revenue, 2020-2023 (USD Million)
10.11.4 Product landscape
10.11.5 Strategic outlook
10.11.6 SWOT analysis
10.12 Pfizer, Inc.
10.12.1 Global overview
10.12.2 Business overview
10.12.3 Financial data
10.12.3.1 Annual sales revenue, 2020-2023 (USD Million)
10.12.4 Product landscape
10.12.5 Strategic outlook
10.12.6 SWOT analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us